Future Market Trends of COPD Therapeutics Market Till 2021

COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-inClass Products Offsets Sales Erosion of Leading Brands Published on – 13 November, 2015 | Number of pages : 122 Single User Price: $4995 “Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world.”

Summary of the Report: Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify longterm disease progression.

There are currently 203 products in active development, excluding four with an unknown stage of development. Although many of the targets identified in the pipeline are well established in the management of COPD, there are some novel, first-in-class targets. This reflects the growing understanding of the underlying mechanisms that characterize the disease.

Click Here To Check Complete Report

Scope of the Report: The COPD market has benefited from notable additions over recent years.

• Which classes of drug dominate the market?

•

What additional benefits have newly approved therapies brought to market?

•

The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.

•

COPD clinical trials have an overall attrition rate of 89.6%.

•

What are the failure rates for individual Phases of clinical development?

•

The COPD market is forecast to rise from a value of $9.2 billion in 2014 to $11.2 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed.

•

How much of a role will disease prevalence and new product approvals play in market growth?

Download Sample Brochure

Reasons to buy: This report will allow you to -

•

Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.

•

Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

•

Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Make an Inquiry Before Buying

COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands

A detailed qualitative analysis of the factors responsible for driving and restraining growth of the COPD Therapeutics Market are provided in the report.

Contact: 1-302-684-6088 sales@marketintelreports.com www.marketintelreports.com

Click here to order a copy of COPD Therapeutics Market Report